What does a high glaucoma risk score from ExomeDNA mean?

A high score means your genetic profile includes variants at loci associated with elevated intraocular pressure or increased susceptibility to optic nerve damage in large population studies. It indicates a higher-than-average statistical likelihood — not a certainty — of developing glaucoma over a lifetime. Regular comprehensive eye exams with IOP and optic nerve evaluation are the most actionable response.

Is glaucoma hereditary?

Yes. First-degree relatives of those experiencing primary open-angle glaucoma carry 3 to 8 times the baseline population risk. Some forms, particularly those linked to MYOC variants, follow an autosomal dominant inheritance pattern. Most glaucoma risk, however, is polygenic — shaped by the cumulative effect of many common variants across the genome rather than a single causal mutation.

What is the MYOC gene and why does it matter for glaucoma?

MYOC encodes myocilin, a glycoprotein secreted by trabecular meshwork cells that regulates aqueous humor drainage from the eye. Pathogenic variants in MYOC's olfactomedin domain cause misfolded protein to accumulate inside these drainage cells, triggering cellular stress and death. The result is impaired aqueous outflow, elevated IOP, and — without treatment — progressive optic nerve damage. MYOC-linked glaucoma tends to be earlier-onset and more clinically severe than typical age-related POAG.

Can lifestyle changes reduce glaucoma risk?

Lifestyle changes can reduce modifiable contributors to glaucoma progression but cannot eliminate genetic susceptibility. The highest-impact actions include: scheduling regular dilated eye exams; managing systemic blood pressure; disclosing all corticosteroid use to your eye doctor; and avoiding sustained prone body positions that transiently raise IOP. Early detection and treatment is the most effective known intervention.

What is intraocular pressure and why does it matter?

Intraocular pressure (IOP) is the fluid pressure inside the eye, maintained by a balance between aqueous humor production and drainage through the trabecular meshwork. In primary open-angle glaucoma, drainage is impaired — often due to genetic variants in genes like MYOC, ABCA1, or RAPGEF5 — causing pressure to build. Elevated IOP compresses optic nerve fibers at the back of the eye, causing progressive, irreversible damage.

How does glaucoma differ from other vision conditions?

Unlike refractive errors or cataracts, glaucoma damages the optic nerve itself — the neural connection between eye and brain. This damage is permanent and cannot be reversed by surgery. Vision loss begins at the periphery and is painless, making self-detection nearly impossible without professional screening. The combination of irreversibility, painlessness, and peripheral onset is what makes genetic risk awareness and regular screening particularly valuable.

Glaucoma Risk and Your Genetics

By the ExomeDNA Science Team | This page contains general information only. For personal health decisions, consult a qualified clinician.

Glaucoma is the leading cause of irreversible blindness worldwide, affecting an estimated 80 million people — yet more than half of those experiencing the condition remain undetected because vision loss begins silently at the periphery, long before it reaches the center of sight. Genetic variants across multiple chromosomal regions influence intraocular pressure (IOP), optic nerve structure, and trabecular meshwork function, collectively shaping an individual's lifetime glaucoma risk. Understanding which variants you carry is a first step toward targeted, proactive eye health monitoring.

What is glaucoma risk?

Glaucoma describes a group of progressive optic neuropathies in which the optic nerve — the cable connecting the eye to the brain — sustains cumulative damage over time. The most prevalent form, primary open-angle glaucoma (POAG, ICD-10: H40.11), develops when the trabecular meshwork, a sponge-like drainage tissue at the front of the eye, fails to clear aqueous humor at a sufficient rate. Fluid accumulates, intraocular pressure rises, and the resulting mechanical and vascular stress gradually destroys retinal ganglion cells and their axons.

The defining clinical feature of POAG is its silence. Elevated IOP causes no pain, and peripheral vision — the first casualty — is so efficiently compensated by the brain that most people do not notice a deficit until 40 percent or more of optic nerve fibers are gone. By the time central visual field is affected, damage is irreversible. This biology makes early detection through regular comprehensive eye exams — including optic nerve evaluation, IOP measurement, and visual field testing — the single most consequential intervention available.

Risk for POAG is shaped by a combination of factors: age (prevalence rises sharply after 60), African and Hispanic ancestry (associated with higher prevalence and more aggressive progression), family history (first-degree relatives of those experiencing glaucoma carry 3 to 8 times the average risk), and genetic architecture at dozens of loci now confirmed through large-scale genome-wide association studies.

The genetics behind glaucoma risk

Six genes with established roles in IOP regulation, trabecular meshwork biology, and optic nerve integrity are represented in this ExomeDNA result.

MYOC (Myocilin) is the most important single gene for open-angle glaucoma in current research. Myocilin is a secreted glycoprotein expressed abundantly in the trabecular meshwork, ciliary body, and retina. Pathogenic variants in the olfactomedin domain of MYOC — the C-terminal region where most disease-causing changes cluster — cause the misfolded protein to accumulate inside trabecular meshwork cells rather than being secreted normally. This misfolded protein triggers endoplasmic reticulum (ER) stress, eventually killing the cells responsible for aqueous drainage. MYOC-linked POAG is autosomal dominant, meaning a single variant copy is sufficient to elevate risk, and tends to be earlier in onset and more severe than typical age-related glaucoma.

ABCA1 encodes ATP-binding cassette transporter A1, a master regulator of cellular cholesterol and lipid efflux. ABCA1 is expressed in trabecular meshwork cells, where lipid homeostasis in the extracellular matrix is essential for maintaining outflow facility. Large GWAS studies have independently linked ABCA1 variants to both intraocular pressure and open-angle glaucoma, suggesting that disrupted lipid transport in the trabecular meshwork may contribute to drainage failure through a mechanism distinct from MYOC misfolding.

HERC2 is a large E3 ubiquitin ligase best known for its regulatory role in pigmentation via its control of the adjacent OCA2 gene. In the glaucoma context, HERC2 variants may influence trabecular pigment deposition. Melanin granules released from the iris pigment epithelium can accumulate in the trabecular meshwork — a hallmark of pigmentary glaucoma — physically obstructing aqueous outflow. HERC2's association with glaucoma risk may reflect this pigmentation-drainage axis.

CADM2 (Synaptic Cell Adhesion Molecule 2) belongs to the immunoglobulin superfamily and plays a role in synapse formation and neurite outgrowth. In the retina, CADM2 may influence the structural integrity of retinal ganglion cell axons — the fibers that comprise the optic nerve. Variants that subtly alter CADM2 function could affect resilience of optic nerve fibers to pressure-induced or vascular injury.

DGKG (Diacylglycerol Kinase Gamma) regulates diacylglycerol (DAG) and phosphatidic acid (PA) concentrations in cells. Lipid signaling in trabecular meshwork cells is an emerging area of glaucoma research; DAG-mediated pathways influence cell contractility, which in turn affects how readily the trabecular meshwork deforms to facilitate outflow.

RAPGEF5 (Rap Guanine Nucleotide Exchange Factor 5) activates Rap GTPases downstream of cAMP/Epac signaling. Trabecular meshwork cell contractility and actin cytoskeleton dynamics are regulated in part through Rap-dependent pathways, making RAPGEF5 a plausible functional candidate for IOP modulation.

What the research says

Research base: Robust.

The genetic architecture of glaucoma has been mapped through some of the largest GWAS efforts in ophthalmology. Two foundational analytical methods underpin the variant associations integrated into this result.

POAG affects approximately 3 percent of adults over age 40 globally, with prevalence rising to roughly 10 percent in adults over 80. It accounts for the majority of irreversible blindness cases in high-income countries, where effective treatments exist but detection remains persistently late.¹

Zhou et al. (2018, PMID 30104761) introduced SAIGE, a scalable mixed-model method that addresses case-control imbalance and cryptic sample relatedness in biobank-scale data — both systematic confounders that, if uncorrected, inflate false-positive rates in disease GWAS. The application of methods in this class to glaucoma phenotypes in the UK Biobank and similar cohorts has substantially increased the credibility of newly identified IOP and POAG loci, including associations at genes such as ABCA1 and RAPGEF5.

Jiang et al. (2021, PMID 34737426) extended this framework through SAIGE-GENE+, a generalized linear mixed model tool optimized for testing rare and common variant aggregates across biobank-scale datasets. This approach improves power to detect gene-level associations where no single variant alone reaches genome-wide significance — particularly relevant for genes like CADM2 and DGKG, where the combined effect of multiple low-frequency variants may account for a meaningful portion of population-level risk variance.

First-degree relatives of those experiencing primary open-angle glaucoma carry 3 to 8 times the baseline population risk. This familial aggregation reflects both polygenic architecture and, in a subset of families, high-penetrance variants in genes such as MYOC that follow Mendelian inheritance patterns.²

The convergence of multiple genes at trabecular meshwork biology — MYOC, ABCA1, DGKG, RAPGEF5 — points to aqueous outflow regulation as the central mechanistic hub of POAG genetics. The inclusion of CADM2 and HERC2 reflects secondary pathways: optic nerve axon integrity and trabecular pigment deposition, respectively. This multi-pathway model is consistent with the clinical heterogeneity of glaucoma and explains why IOP alone does not fully predict who will develop vision loss.

How glaucoma risk affects you

Polygenic risk for glaucoma does not determine outcome — it calibrates surveillance. The eye care system has highly effective interventions (IOP-lowering drops, selective laser trabeculoplasty, surgical drainage procedures) that demonstrably slow or halt glaucomatous vision loss when initiated before significant nerve fiber layer damage has occurred. The tragedy of glaucoma is not the absence of treatment but the absence of timely detection.

Those experiencing elevated genetic risk for glaucoma — particularly those who also carry a family history of the condition, are of African or Hispanic ancestry, or have other known risk factors — benefit most from shifting from reactive to proactive eye health monitoring. The optic nerve can tolerate a surprising amount of cumulative damage before visual function becomes symptomatic; this means that the window for effective intervention is open, but it is not permanent.

Intraocular pressure is the key modifiable risk factor in POAG. Even among those with normal-tension glaucoma — a subtype where optic nerve damage occurs despite statistically "normal" IOP — lowering IOP further reduces the rate of progression. Every gene in this panel except CADM2 has a plausible connection to IOP physiology, reinforcing IOP as the upstream target for both clinical management and lifestyle modification.

Vascular factors also matter. Optic nerve head perfusion depends on the balance between IOP and blood pressure. Both systemic hypertension and hypotension can impair optic nerve blood flow; nocturnal blood pressure dips are particularly implicated in normal-tension glaucoma progression. Sleep position has a modest but measurable effect on IOP — sustained prone positioning (face-down) raises IOP transiently, which may be relevant for those with already-elevated pressures.

Corticosteroids — whether topical (eye drops), inhaled, or systemic — can raise IOP in a subset of individuals known as "steroid responders." Those with elevated glaucoma genetic risk should ensure their eye care provider is informed of any corticosteroid use, however brief or seemingly unrelated to eye health.

Working with your glaucoma risk result

A higher glaucoma risk score warrants a structured, proactive approach to eye health. The following modifiers are listed in order of impact:

Schedule comprehensive dilated eye exams annually or as directed by an ophthalmologist. For those with elevated genetic risk or family history, baseline optic nerve imaging (OCT of the retinal nerve fiber layer) and visual field testing before age 40 establishes the reference against which future change is measured.
Know your baseline intraocular pressure. IOP fluctuates across the day (diurnal variation); a single normal reading does not rule out pressure spikes. Ask about phased tonometry or home IOP monitoring if your eye doctor considers it appropriate.
Manage systemic blood pressure and avoid nocturnal hypotension. If you take antihypertensive medication, confirm with your prescribing clinician that evening dosing does not cause excessive blood pressure dips overnight, which can impair optic nerve perfusion.
Disclose all corticosteroid use to your eye care provider. Steroid responders may experience clinically significant IOP elevation even from nasal sprays or inhaled corticosteroids. Knowing your baseline IOP before any steroid course provides a critical reference.
Protect eyes from traumatic injury. Secondary angle-closure and traumatic glaucoma can develop years after blunt eye trauma; appropriate protective eyewear during sports and high-risk activities reduces this risk.
Avoid sustained prone or inverted body positions for those with known elevated IOP. Yoga inversions and extended prone sleeping have been shown in small studies to raise IOP transiently; for those with borderline pressures, this behavioral modification is low-cost and low-risk.

Glaucoma risk shares genetic architecture with several related traits measurable through ExomeDNA. Intraocular pressure as a continuous quantitative trait is genetically correlated with POAG status; many of the same loci — including those at ABCA1 and MYOC — influence both. Optic disc morphology (cup-to-disc ratio) is another heritable intermediate phenotype that reflects optic nerve head anatomy and is predictive of glaucoma susceptibility independent of IOP.

The HERC2 locus overlaps substantially with pigmentation genetics. Eye color — particularly iris pigment density — is one of the strongest individual determinants of pigmentary glaucoma risk. Lighter irides are associated with greater pigment dispersion from the posterior iris surface, raising the probability of trabecular pigment accumulation over decades.

CADM2 appears in GWAS results for several neurological and neurodevelopmental traits. Its role in retinal ganglion cell axon maintenance may connect glaucoma vulnerability to broader optic nerve resilience, relevant also to other optic neuropathies.

For individuals with MYOC-linked risk, genetic counseling regarding family members is appropriate, given the autosomal dominant pattern of high-penetrance MYOC variants.

References

Zhou W, et al. (2018). Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. Nature Genetics. PMID 30104761.
Jiang L, et al. (2021). A generalized linear mixed model association tool for biobank-scale data. Nature Genetics. PMID 34737426.

Data sources: GWAS Catalog; dbSNP; NCBI Gene; ClinVar; OMIM.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.

Browse all traits →